Compare SXT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXT | CNTA |
|---|---|---|
| Founded | 1882 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | N/A | 2021 |
| Metric | SXT | CNTA |
|---|---|---|
| Price | $98.33 | $24.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $110.00 | $38.00 |
| AVG Volume (30 Days) | 183.5K | ★ 1.4M |
| Earning Date | 02-13-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 56.32 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $1,595,084,000.00 | $15,000,000.00 |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $5.94 | N/A |
| P/E Ratio | $29.87 | ★ N/A |
| Revenue Growth | 4.25 | ★ 118.88 |
| 52 Week Low | $67.61 | $9.60 |
| 52 Week High | $121.54 | $30.58 |
| Indicator | SXT | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 55.43 |
| Support Level | $94.74 | $21.50 |
| Resistance Level | $97.63 | $22.47 |
| Average True Range (ATR) | 2.39 | 1.07 |
| MACD | 0.18 | 0.24 |
| Stochastic Oscillator | 77.05 | 85.58 |
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are; Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.